Article
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
The Journal of clinical endocrinology and metabolism - 1 Aug 2006
Akintoye Sunday O, Kelly Marilyn H, Brillante Beth, Cherman Natasha, Turner Sarah, Butman John A, Robey Pamela G, Collins Michael T
Abstract excerpt
CONTEXT: GH excess affects approximately 20% of the patients with McCune-Albright syndrome (MAS). MAS is caused by sporadic, postzygotic, activating mutations in the GNAS gene, which codes for the cAMP-regulating protein, G(s)alpha (gsp oncogene). These same mutations are found in approximately one third of the sporadic cases of acromegaly. OBJECTIVE: We examined efficacy of the GH receptor antagonist,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.